Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB
Mandate

Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB

September 03, 2018 M&A

Vinge together with the Norwegian law firm Schjodt advises the Norwegian pharmaceuticals company Ultimovacs AS in connection with its acquisition of the immunotherpay business of the Uppsala based company Immuneed AB.

The business focuses on the development of vaccine for the treatment and potential prevention of cancer.

Vinge's team consisted primarily of the partner Jonas Johansson and the associates Carl Sander and Fredric Reismüller.

Related

Vinge advises the financing banks in connection with Verdane and Telenor’s partnership in Telenor Connexion

 Vinge has advised a syndicate of Nordic and Northern European banks connection with the financing of Verdane and Telenor’s new partnership relating to Telenor Connexion. Under the partnership, Verdane and Telenor will jointly invest in Telenor Connexion, a leading provider of IoT solutions. The transaction was completed on 10 September 2026 and values Telenor Connexion at SEK 7.5 billion.
September 23, 2026

Vinge advises Accru Partners on its EUR 550 million senior secured bond issuance

 Vinge advises Accru Partners, backed by Axcel, in connection with Accru Partners’ inaugural EUR 550 million issuance of senior secured bonds.
September 23, 2026

Vinge advises Sveafastigheter on EUR 350 million bond issuance

 Vinge has advised Sveafastigheter AB (publ) on the issuance of EUR 350 million in senior unsecured bonds under its existing EUR 2 billion EMTN programme.
September 23, 2026